AUSTIN, Texas, March 30, 2017 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of a new class of targeted biologic therapies that possess unique mechanisms of action in oncology, announces a list of poster presentations featuring MT-3724, an ETB targeting CD20, and MT-4019, a second generation (Engineered Toxin Body) ETB targeting CD38, at the upcoming American Association for Cancer Research (AACR) Annual Meeting, being held April 1-5, 2017, in Washington, D.C.
The abstracts feature preclinical data on the effect of MT-3724 in mantle cell lymphoma as well as a study on the potential to prolong drug exposure in combination with sirolimus. The abstract for MT-4019 includes new data on the 2nd-generation de-immunized ETB scaffold, efficacy in daratumumab sensitive and resistant cells lines, and activity in sequential combination with daratumumab.
Below are details of the three poster presentations at the 2017 AACR conference:
MT-4019: a de-immunized engineered toxin body targeting CD38 for multiple myeloma
Abstract Number: 2659
Location: Section 26
Session Date & Time: Monday, April 3 from 1:00 - 5:00 PM ET
Preclinical examination of the effects of MT-3724, an engineered toxin body targeting CD20, in mantle cell lymphoma
Abstract Number: 3651
Location: Section 26
Session Date & Time: Tuesday, April 4 from 8:00 - 12:00 PM ET
Combination of MT-3724 with sirolimus reduces anti-drug antibody response and prolongs drug exposure
Abstract Number: 1644
Location: Section 27
Session Date & Time: Monday, April 3 from 8:00 - 12:00 PM ET
“We are excited to present these preclinical data showcasing the differentiated approach of our Engineered Toxin Body platform technology. We are particularly excited to share new data for MT-4019, the first of our 2nd generation de-immunized ETBs that targets the CD38 receptor for multiple myeloma. We believe this 2nd generation de-immunized ETB scaffold will allow the company to expand the development of our ETBs to solid tumor indications as well,” said Eric Poma, CEO and CSO, Molecular Templates. “The preclinical data for MT-3724 provides further support for the promising signals of efficacy we observed in our Phase 1 study. We look forward to continuing enrollment in our ongoing Phase 1 study focused on diffuse large B-cell lymphomas (DLBCL) as well as initiating our Phase 2 program before year end.”
MT-3724 is Molecular Templates' lead drug candidate. MT-3724 is in a Phase 1 clinical trial in heavily pre-treated non-Hodgkin's lymphoma patients at the Memorial Sloan-Kettering Cancer Center, the MD Anderson Cancer Center, the Lineberger Comprehensive Cancer Center at the University of North Carolina, and the University of Arizona. An expansion arm of the Phase 1 study focused on relapsed and refractory diffuse large lymphoma patients is set to commence enrollment. More information is available at clinicaltrials.gov.
MT-4019 is Molecular Templates' preclinical drug candidate targeting CD38. MT-3724 has been awarded a $15.2 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT) to fund development. MT-4019 represents the second generation of Engineered Toxin Bodies (ETBs) that incorporate a proprietarily de-immunized scaffold.
About Molecular Templates
Molecular Templates is focused on the discovery, development, and commercialization of next-generation immunotoxins called Engineered Toxin Bodies (ETBs) for the treatment of cancers and other serious diseases. Santé Ventures is the lead equity investor in Molecular Templates; Excel Venture Management and AJU IB Life Sciences Overseas Expansion Platform Fund are also equity investors in Molecular Templates. For additional information, please visit the Company's website at www.mtem.com.
CONTACT: Investor Contact: Andrew McDonald, Ph.D. email@example.com 646.597.6987